Weal and woe of interleukin-18 in the T cell therapy of cancer
Christoph Kessel, Claudia Rössig, Hinrich Abken
Abstract
Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a double-edged sword in CAR T cell therapies.
Topics & Concepts
Chimeric antigen receptorMedicineT cellCancerClinical trialImmunologyImmunotherapyCancer researchOncologyInternal medicineImmune systemCAR-T cell therapy researchCutaneous lymphoproliferative disorders researchImmune Cell Function and Interaction